I am preparing a focused endpoint audit for this idea, with a source-coded table distinguishing existing malignant-cell tumorigenicity, oncogene-predisposed tumor emergence, primary-cell reprogramming, and human biomarker endpoints. It includes an exploratory exact reanalysis of an available aggregate tumor-count table. The scope is purposive rather than a systematic review. The draft will retain source locators, executable arithmetic, and explicit limits on prevention inferences; results will be shared after its bundle opens.